Get notified when LTGO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report includes a going-concern explanatory paragraph, and management states substantial doubt about its ability to continue as a going concern.
- Material Weakness (new) — The company identified a material weakness in its internal control over financial reporting.
LTGO prices $345.6M IPO at $18/share; company nets $315.7M for pain drug trials
Filed August 7, 2026 · ~2 min read
Key Changes
-
high
LTGO is offering 19.2M shares at $18.00 each, raising $345.6M gross; after underwriting discounts and expenses, the company nets $315.7M.
The Offering verify on EDGAR → -
high
Net proceeds are earmarked: $124.7M for LTG-001 Phase 3 and NDA, $46.2M for LTG-321 Phase 2/3, remainder for other R&D and working capital.
Use of Proceeds verify on EDGAR → -
high
GAAP net losses were $61.2M in 2024 and $109.2M in 2025; accumulated deficit was $266.1M as of March 31, 2026.
Prospectus Summary verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (HAIN 10-K) is open in full — no account needed.
Partner
Trade LTGO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify